Medical News

RSS

Website launched to track aid to Haiti from 'pledge to impact'

Agence France-Presse reports that the U.N. has launched "a new website to track the estimated 9.9 billion dollars in aid pledged to Haiti by the international community in the wake of a devastating January 12 earthquake." The website is a joint project of the Haitian government and the U.N. Development Programme.

23 Apr 2010

Seasonal flu vaccine causing serious side effects in under-fives: Ban on flu vaccination program

The seasonal flu vaccine has caused serious side effects in dozens of children in Western Australia (WA) and following this the Health Department has suspended further free flu vaccinations for under-fives. There has been as rise in admissions to Princess Margaret Hospital. The side effects to the flu vaccine include fever, vomiting and often seizures related to high fever, also known as febrile convulsions. One of the children is seriously ill at present.

22 Apr 2010

Zimmer reports increase of 7.1% in net sales for first-quarter

Zimmer Holdings, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported first quarter net sales of $1.06 billion, an increase of 7.1% reported and 3.4% constant currency over the first quarter of 2009. Diluted earnings per share for the quarter were $1.01 reported and $1.02 adjusted, an increase of 7.4% adjusted over the prior year period.

22 Apr 2010

AB SCIEX to collaborate in disease studies with Samuel Lunenfeld Research Institute of Mount Sinai Hospital

AB SCIEX, a global leader in life science analytical technologies, today announced that it is collaborating with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, one of the world's leading centers for biomedical research, to improve disease studies. The project is focused on better understanding cancer, diabetes and heart disease by advancing the study of proteins through the use of an emerging mass spectrometry platform currently under development by AB SCIEX.

22 Apr 2010

Karo Bio reports net loss of MSEK 40.5 for January–March 2010

KARO BIO'S PROJECTS ARE PROGRESSING

22 Apr 2010

Align Technology reports 28.5% increase year-over-year in first-quarter revenues

Align Technology, Inc. today reported financial results for the first quarter of fiscal 2010, ended March 31, 2010.

22 Apr 2010

Codexis prices initial common stock public offering at $13.00 per share

Codexis, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock, at $13.00 per share. All shares are being sold by the company. Codexis has granted the underwriters an option to purchase up to an additional 900,000 shares at the initial public offering price to cover overallotments, if any. The common stock will trade on the NASDAQ Global Market under the symbol "CDXS."

22 Apr 2010

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Mystic Pharmaceuticals today announced it has been granted U.S. Patent 7,669,597, a key technology of its VRx2™ drug delivery platform. The VRx2™ Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.

22 Apr 2010

First Edition: April 22, 2010

Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes about the Money Follows The Person program: "Richard Hasselbach and Deborah Kadlec met in a nursing home and dreamed of a life together outside its walls. Their health conditions made living on their own a challenge: Hasselbach, 63, is disabled from a stroke and lost a leg to a blocked artery. Kadlec, 52, has multiple sclerosis. They both use wheelchairs and need help with chores such as bathing, cooking and remembering to take their medicines.

22 Apr 2010

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Baxter International Inc. today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.

From Baxter International Inc. 22 Apr 2010

New gene therapy to restore retinal cone function and day vision

Veterinary ophthalmology researchers from the University of Pennsylvania have used gene therapy to restore retinal cone function and day vision in two canine models of congenital achromatopsia, also called rod monochromacy or total color blindness.

22 Apr 2010

Cognitive behavior therapy works better as couples therapy for alcohol-dependent women

Barbara McCrady and Elizabeth Epstein wanted to know whether cognitive behavior therapy worked better for alcohol-dependent women when delivered as couples therapy than when delivered as individual therapy. They reported recently that both treatment methods worked well, but women treated in couples therapy maintained their gains a bit better than those in individual therapy. Also, women suffering from depression in addition to alcohol-dependence did better in couples therapy. Their paper appeared recently in the Journal of Consulting and Clinical Psychology.

22 Apr 2010

Manduka launches new MatWare Mat Sleeve

Manduka, the world's leader in high performance yoga gear, announced today the launch of the new MatWare Mat Sleeve—the latest addition to its ergonomically inspired MatWare line of yoga mat carriers. Designed for the yogi who likes to keep their yoga mat protected while on the go, the MatWare Mat Sleeve—like all Manduka products—is sleek, convenient, innovative and earth friendly.

22 Apr 2010

Valor Medical's European cerebral aneurysm clinical trial finalized with 30 patients treated

Valor Medical's CEO, H. Clark Adams, announced today that Valor's European clinical trial was finalized with 30 patients treated. Mr. Adams stated, "The trial took longer than expected because there are current approved therapies which were used as a first line of therapy. Patients who were enrolled to be treated with Valor's Neucrylate were not always acceptable candidates for these standard-of-care therapies.

22 Apr 2010

Interventional Spine to present at and participate as sponsor of Spine Technology Summit

Interventional Spine, Inc., a privately held medical device manufacturer focusing on diseases of the spine, will present at the Spine Technology Summit at the Roosevelt Hotel in New Orleans on Monday April 26th. This annual event is a showcase for 40 new technology companies and attracts investors, industry, practitioners and analysts.

22 Apr 2010

FDA announces draft guidance expanding transparency, disclosure in conflict of interest waivers

The U.S. Food and Drug Administration today announced draft guidance that would expand transparency and disclosure when the agency grants a conflict of interest waiver to permit an individual's participation at an FDA advisory committee meeting.

22 Apr 2010

CancerDrugsDirect.com provides customers access to affordable cancer medications

When someone is diagnosed with cancer, the effects can be devastating both physically as well as financially. Recent studies have shown that many cancer patients are foregoing care because of the skyrocketing cost of cancer treatments.

22 Apr 2010

The Sports Club reports 6.4% decrease in first-quarter 2010 revenues

The Sports Club Company, Inc. today announced financial results for the first quarter ended March 31, 2010.

22 Apr 2010

Accredo Health Group selected as sole specialty pharmacy provider of Epoprostenol for Injection

Actelion Pharmaceuticals US, Inc., today announced that it has selected Accredo Health Group, Inc., a wholly-owned subsidiary of Medco Health Solutions, Inc., to serve as the sole specialty pharmacy provider of Epoprostenol for Injection, the only epoprostenol formulated to provide up to 24-hour stability at room temperature without the use of ice packs.

22 Apr 2010

Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

Vical Incorporated announced today that the company's TransVax cytomegalovirus vaccine elicited sustained increases in both cellular and antibody immune responses compared with placebo through the final 12-month follow-up in an ongoing Phase 2 trial in hematopoietic cell transplant recipients.

22 Apr 2010

Medical News

Website launched to track aid to Haiti from 'pledge to impact'

Seasonal flu vaccine causing serious side effects in under-fives: Ban on flu vaccination program

Zimmer reports increase of 7.1% in net sales for first-quarter

AB SCIEX to collaborate in disease studies with Samuel Lunenfeld Research Institute of Mount Sinai Hospital

Karo Bio reports net loss of MSEK 40.5 for January–March 2010

Align Technology reports 28.5% increase year-over-year in first-quarter revenues

Codexis prices initial common stock public offering at $13.00 per share

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

First Edition: April 22, 2010

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

New gene therapy to restore retinal cone function and day vision

Cognitive behavior therapy works better as couples therapy for alcohol-dependent women

Manduka launches new MatWare Mat Sleeve

Valor Medical's European cerebral aneurysm clinical trial finalized with 30 patients treated

Interventional Spine to present at and participate as sponsor of Spine Technology Summit

FDA announces draft guidance expanding transparency, disclosure in conflict of interest waivers

CancerDrugsDirect.com provides customers access to affordable cancer medications

The Sports Club reports 6.4% decrease in first-quarter 2010 revenues

Accredo Health Group selected as sole specialty pharmacy provider of Epoprostenol for Injection

Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News